A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis

Journal of Bone and Mineral Research

Volumn 24, Issue 10, 2009, Pages 1662-1671

  Eddleston, Alison ^a   Marenzana, Massimo ^a   Moore, Adrian R ^a   Stephens, Paul ^a   Muzylak, Mariusz ^a   Marshall, Diane ^a   Robinson, Martyn K ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Antibody; Colitis; Inflammation; SCID; Sclerostin

Indexed keywords

NEUTRALIZING ANTIBODY; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; SCLEROSTIN; SCLEROSTIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DENSITY; BONE STRENGTH; CELL STIMULATION; COLITIS; CONTROLLED STUDY; ENERGY YIELD; FEMALE; FEMUR; HISTOPATHOLOGY; LOAD CARRYING CAPACITY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; TRABECULAR BONE; WEIGHT REDUCTION; YOUNG MODULUS;

ANIMALS; ANTIBODIES; BIOLOGICAL MARKERS; BIOMECHANICS; BONE AND BONES; BONE MORPHOGENETIC PROTEINS; BONE RESORPTION; COLITIS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC MARKERS; MICE; MICE, INBRED BALB C; MICE, SCID; X-RAY MICROTOMOGRAPHY;

EID: 70349920691     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.090403     Document Type: Article

References (41)

1. Compston JE, Judd D, Crawley EO, Evans WD, Evans C, Church HA, Reid EM, Rhodes J 1987 Osteoporosis in patients with inflammatory bowel disease. Gut 28:410-415. (Pubitemid 17056874)
2. Lichtenstein GR 2003 Evaluation of bone mineral density in inflammatory bowel disease: Current safety focus. Am J Gastroenterol 98:S24-S30. (Pubitemid 38044604)
3. Boot AM, Bouquet J, Krenning EP, de Muinck Keizer-Schrama SMPF 1998 Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 42:188-194. (Pubitemid 28214002)
4. Vogelsang H, Ferenci P, Woloszczuk W, Resch H, Herold C, Frotz S, Gangl A 1989 Bone disease in vitamin D-deficient patients with Crohn's disease. Dig Dis Sci 34:1094-1099. (Pubitemid 19188893)
5. Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F 1995 Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J Bone Miner Res 10:250-256.
6. Ghosh S, Cowen S, Hannan WJ, Ferguson A 1994 Low bone mineral density in Crohns' disease, but not ulcerative colitis, at diagnosis. Gastroenterology 107:1031-1039. (Pubitemid 24294565)
7. Lamb EJ, Wong T, Smith DJ, Simpson DE, Coakley AJ, Moniz C, Muller AF 2002 Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 16:1895-1902. (Pubitemid 35253005)
8. Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C 1997 Reduced bone density in patients with inflammatory bowel disease. Gut 40:228-233. (Pubitemid 27093099)
9. Paganelli M, Albanese C, Borrelli O, Civitelli F, Canitano N, Viola F, Passariello R, Cucchiara S 2007 Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 13:416-423. (Pubitemid 46668246)
10. De Benedetti F, Rucci N, Del Fattore A, Peruzzi B, Paro R, Longo M, Vivarelli M, Muratori F, Berni S, Ballanti P, Ferrari S, Teti A 2006 Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 54:3551-3563. (Pubitemid 44737167)
11. Kwan Tat S, Padrines M, Theoleyre S, Heymann D, Fortun Y 2004 IL-6, RANKL, TNF-alpha/IL-1: Interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 15:49-60.
12. Ragab AA, Nalepka JL, Bi Y, Greenfield EM 2002 Cytokines synergistically induce osteoclast differentiation: Support by immortalized or normal calvarial cells. Am J Physiol Cell Physiol 283:C679-C687. (Pubitemid 34920301)
13. Moschen AR, Kaser A, Enrich B, Ludwiczek O, Gabriel M, Obrist P, Wolf AM, Tilg H 2005 The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 54:479-487. (Pubitemid 40395499)
14. Compston J 2003 Osteoporosis in inflammatory bowel disease. Gut 52:63-64.
15. van Staa TP, Cooper C, Brusse LS, Leufkens H, Javaid MK, Arden NK 2003 Inflammatory bowel disease and the risk of fracture. Gastroenterology 125:1591-1597. (Pubitemid 37500422)
16. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow M, Latham J 2003 Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276. (Pubitemid 37522584)
17. Hamersma H, Gardner J, Beighton P 2003 The natural history of sclerosteosis. Clin Genet 63:192-197.
18. Balemans W, Ebeling M, Patel N, Van Hul E, Olsen P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W 2001 Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537-543. (Pubitemid 32184286)
19. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersama H, Beighton P, Mulligan J 2001 Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine-knot containing protein. Am J Hum Genet 68:577-589. (Pubitemid 32202753)
20. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, Wu D 2005 Sclerostin binds to LRP5/6 and antagonises canonical Wnt signalling. J Biol Chem 280:19883-19887. (Pubitemid 41379516)
21. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, Krumlauf R 2006 Bone density ligand Sclerostin directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 21:1738-1749. (Pubitemid 46141229)
22. Semenov MV, He X 2006 LRP5 mutations linked to hight bone mass diseases cause reduced binding and inhibition by SOST. J Biol Chem 281:38276-38284. (Pubitemid 46043307)
23. Baron R, Rawadi G, Roman-Roman S 2006 Wnt signalling a: A key regulator of bone mass. Curr Top Dev Biol 76:103-127. (Pubitemid 44760540)
24. Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippet JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ, Carding SR 2003 Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19:849-861.
25. Dresner-Pollak R, Gelb N, Rachmilewitz D, Karmeli F, Weinreb M 2004 Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. Gastroenterology 127:792-801. (Pubitemid 39208412)
26. Byrne FR, Morony S, Warmington K, Geng Z, Brown HL, Flores SA, Fiorino M, Yin SL, Hill D, Porkess V, Duryea D, Pretorius JK, Adamu S, Manoukian R, Danilenko DM, Sarosi I, Lacey DL, Kostenuik PJ, Senaldi G 2005 CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin. Gut 54:78-86. (Pubitemid 40007222)
27. Babcook JS, Leslie KB, Olsen OA, Salmon RA, Schrader JW 1996 A novel Strategy for generating monoclonal antibodies from single lymphocytes producing antibodies of defined specificity. Proc Natl Acad Sci USA 93:7843-7848.
28. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD 2009 Characterisation of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284:10890-10900.
29. Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL 1993 Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C.B-17 SCID mice. Int Immunol 5:1461-1471. (Pubitemid 23325202)
30. R cells suppress innate immune pathology through cytokine-dependent mechanisms. J Exp Med 197:111-119.
31. Tilg H, Kaser A, Pines A, Dotan I 2008 Gut, inflammation and osteoporosis: Basic and clinical concepts. Gut 57:684-694. (Pubitemid 351579985)
32. Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG, Awad HA, Yanoso L, Zhao L, Schwarz EM, Zhang YE, Boyce BF, Xing L 2008 Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteosomal degradation of bone morphogenic signalling proteins. J Biol Chem 283:23084-23092.
33. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C 2008 Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860-869. (Pubitemid 351768804)
34. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu Q-T, Ke HK, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2009 Sclerostin antibody treatment increases bone formation, bone mass and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 24:578-588.
35. Ominsky M, Stouch B, Doellgast G, Gong J, Cao J, Gao Y, Tipton B, Haldankar R, Winters A, Ho S, Chen Q, Graham K, Hara S, Deshpande R, Zhou L, Hale M, Henry A, Stephens P, Lawson A, Lightwood D, Perkins V, Kirby H, Moore A, Popplewell A, Robinson M, Vlasseros F, Jolette J, Smith SY, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2006 Administration of sclerostin monoclonal antibodies to female cynomolgus monkeys results in increased bone formation, bone mineral density and bone strength. J Bone Miner Res 21:S1:S44.
36. Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson M, Harris S, Posvar E 2007 Anti-sclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Res 22:S1;S37.
37. Warmington K, Ominsky M, Bolon B, Cattley R, Stephens P, Lawson A, Lightwood D, Perkins V, Kirby H, Moore A, Robinson M, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C 2005 Sclerostin monoclonal antibody treatment of osteoporotic rats completely reverses one year of ovariectomy-induced systemic bone loss. J Bone Miner Res 20:S1;S22.
38. Bennett CN, Ouyang H, Ma YL, Zeng Q, Gerin I, Sousa KM, Lane TF, Krishnan V, Hankenson KD, MacDougald OA 2007 Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J Bone Miner Res 22:1924-1932. (Pubitemid 351229309)
39. Kim JB, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, Helms JA 2007 Bone regeneration is regulated by Wnt signalling. J Bone Miner Res 22:1913-1923. (Pubitemid 351229308)
40. Holmem SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO 2005 Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 280:21162-21168. (Pubitemid 40805677)
41. Spencer GJ, Utting JC, Etheridge SL, Arnett TR, Genever PG 2006 Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 119:1283-1296.